Display options
Cite
Jung HK, Lee KJ, Choi MG, et al. Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study. J Neurogastroenterol Motil. 2016;22(2):254-63doi: 10.5056/jnm15178.
Jung, H. K., Lee, K. J., Choi, M. G., Park, H., Lee, J. S., Rhee, P. L., Kim, N., Park, K., Choi, S. C., Lee, O. Y., Huh, K. C., Song, G. A., Hong, S. J., Sohn, C. I., Jung, H. Y., Lee, Y. C., Rew, J. S., Jee, S. R., & Kwon, J. G. (2016). Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study. Journal of neurogastroenterology and motility, 22(2), 254-63. https://doi.org/10.5056/jnm15178
Jung, Hye-Kyung, et al. "Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study." Journal of neurogastroenterology and motility vol. 22,2 (2016): 254-63. doi: https://doi.org/10.5056/jnm15178
Jung HK, Lee KJ, Choi MG, Park H, Lee JS, Rhee PL, Kim N, Park K, Choi SC, Lee OY, Huh KC, Song GA, Hong SJ, Sohn CI, Jung HY, Lee YC, Rew JS, Jee SR, Kwon JG. Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study. J Neurogastroenterol Motil. 2016 Apr 30;22(2):254-63. doi: 10.5056/jnm15178. PMID: 26811504; PMCID: PMC4819864.
Copy Download .nbib Format: NLM
Share it on

J Neurogastroenterol Motil. 2016 Apr 30;22(2):254-63. doi: 10.5056/jnm15178.

Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study.

Journal of neurogastroenterology and motility

Hye-Kyung Jung, Kwang Jae Lee, Myung-Gyu Choi, Hyojin Park, Joon Seong Lee, Poong-Lyul Rhee, Nayoung Kim, KyungSik Park, Suck Chei Choi, Oh Young Lee, Kyu Chan Huh, Geun Am Song, Su Jin Hong, Chong Il Sohn, Hwoon-Yong Jung, Yong Chan Lee, Jong Sun Rew, Sam Ryong Jee, Joong Goo Kwon

Affiliations

  1. Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
  2. Department of Gastroenterology, Ajou University School of Medicine, Suwon, Gyeonggi-do, Korea.
  3. Department of Internal Medicine, Catholic University College of Medicine, Seoul, Korea.
  4. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  5. Department of Internal Medicine, Soonchunhyang University College, Seoul, Korea.
  6. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  7. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
  8. Department of Internal Medicine, Keimyung University College of Medicine, Daegu, Korea.
  9. Department of Internal Medicine, Wonkwang University College of Medicine, Iksan, Jeollabuk-do, Korea.
  10. Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
  11. Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
  12. Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea.
  13. Department of Internal Medicine, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  14. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  15. Chonnam National University Medical School, Gwangju, Korea.
  16. Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.
  17. Department of Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, Korea.

PMID: 26811504 PMCID: PMC4819864 DOI: 10.5056/jnm15178

Abstract

BACKGROUND/AIMS: The effect of proton pump inhibitors (PPI) in Asian functional dyspepsia (FD) patients has not been well established as in Westerncountries. DA-9701, a novel prokinetic agent, stimulates gastric emptying and modulates visceral hypersensitivity in vivo and in human studies. This study was conducted to compare the efficacy of DA-9701 with a conventional PPI in mono or combination therapy in patients with FD.

METHODS: In this double-blind, randomized, non-inferiority trial, 389 patients diagnosed with FD using Rome III criteria were allocated among3 groups: 30-mg DA-9701 t.i.d (means 3 times a day), 40-mg pantoprazole, and 30-mg DA-9701 t.i.d + 40-mg pantoprazole. Theprimary efficacy end-point was a global assessment of the patient binary response or response on a 5-Likert scale after 4 weeks.

RESULTS: The global symptomatic improvement was 60.5% in the DA-9701 group, 65.6% in the pantoprazole group, and 63.5% in the DA-9701 + pantoprazole group using a 5-Likert scale at week 4 with no significant difference among 3 groups (P = 0.685). Symptomimprovement measured by binary outcome was significantly achieved in each of the 3 groups, but not different among groups.Patients in all treatment groups reported significant improvement in the response rate and symptoms according to FD subtypes anddyspepsia-related quality of life (P < 0.001), but there were no significant differences among the 3 groups.

CONCLUSIONS: DA-9701 improves global and individual symptoms and increases dyspepsia-specific quality of life in patients with FD. The efficacyof DA-9701 monotherapy is comparable with pantoprazole and there is no additive effect with combination of DA-9701 andpantoprazole in patients with FD.

Keywords: DA-9701 (Motilitone); Dyspepsia; Proton pump inhibitor

References

  1. Gastroenterology. 2006 Apr;130(5):1466-79 - PubMed
  2. Gut. 1995 Apr;36(4):534-8 - PubMed
  3. Scand J Gastroenterol Suppl. 1991;182:17-24 - PubMed
  4. J Neurogastroenterol Motil. 2011 Jul;17(3):245-51 - PubMed
  5. N Engl J Med. 2006 Feb 23;354(8):832-40 - PubMed
  6. J Clin Gastroenterol. 1987 Jun;9(3):303-9 - PubMed
  7. Phytomedicine. 2008 Oct;15(10):836-43 - PubMed
  8. Gut. 2000 Oct;47(4):473-80 - PubMed
  9. J Neurogastroenterol Motil. 2010 Jul;16(3):251-7 - PubMed
  10. Korean J Gastroenterol. 2004 Mar;43(3):160-7 - PubMed
  11. Gut. 2008 Jun;57(6):740-6 - PubMed
  12. Am J Gastroenterol. 2005 Oct;100(10):2324-37 - PubMed
  13. PLoS One. 2015 Sep 24;10(9):e0138927 - PubMed
  14. J Neurogastroenterol Motil. 2015 Jul 30;21(3):414-22 - PubMed
  15. J Neurogastroenterol Motil. 2015 Jul 30;21(3):330-6 - PubMed
  16. Tohoku J Exp Med. 2014;234(3):237-40 - PubMed
  17. BMC Gastroenterol. 2012 May 01;12 :42 - PubMed
  18. Biol Pharm Bull. 2010;33(6):958-62 - PubMed
  19. Gut Liver. 2014 Jul;8(4):388-93 - PubMed
  20. J Gastroenterol. 2011 Feb;46(2):183-90 - PubMed
  21. Biomol Ther (Seoul). 2013 May 30;21(3):181-9 - PubMed
  22. J Gastroenterol Hepatol. 2012 Apr;27(4):766-72 - PubMed
  23. Gut. 2002 Oct;51(4):502-6 - PubMed
  24. J Gastroenterol. 2010 Apr;45(4):413-21 - PubMed
  25. Clin Gastroenterol Hepatol. 2007 Feb;5(2):178-85; quiz 140 - PubMed
  26. Aliment Pharmacol Ther. 1998 Nov;12(11):1055-65 - PubMed
  27. Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8 - PubMed
  28. Gastroenterology. 2004 Oct;127(4):1239-55 - PubMed
  29. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001960 - PubMed

Publication Types